UP0 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
High Product-level Gross MarginsVery high TTM gross margin (~84%) reflects durable product economics in ultra-rare therapies. As revenue scales across approved indications, these margins support long-term profitability potential, funding of launches and R&D without requiring equivalent increases in COGS.
Established Global Commercial FootprintSales across 35+ countries and growing patient counts for Crysvita, Dojolvi and Evkeeza indicate durable market access and payer reimbursement traction. Diversified geography and established specialty channels reduce single-market dependency and support multi-year revenue scaling.
Near-term Regulatory And Clinical CatalystsTwo imminent PDUFA decisions and an advancing gene-therapy manufacturing ramp create structural upside: approvals could expand addressable markets and drive durable revenue steps, while in-house manufacturing readiness lowers commercial execution risk post-approval.
Bears Say
Sustained Negative Operating Cash FlowLarge negative operating and free cash flow signals ongoing cash burn that will persist until profitability or large non-operating receipts occur. This increases reliance on external financing or asset monetization and heightens funding risk across 2–6 months.
Weakened Balance Sheet And High LeverageNegative equity and roughly $1.2B of debt materially reduce financial flexibility, limit capacity to absorb setbacks, and raise refinancing risk. Sustained losses could exacerbate leverage, constraining strategic options and increasing cost of capital.
Profitability Dependent On PRV Monetization & LaunchesManagement's path to 2027 profitability assumes monetizing two PRVs and successful near-term launches. Delays, lower-than-expected PRV proceeds, or launch/regulatory setbacks would push funding needs and timeline, making profitability contingent on execution and one-off receipts.
Ultragenyx Pharmaceutical News
UP0 FAQ
What was Ultragenyx Pharmaceutical, Inc.’s price range in the past 12 months?
Currently, no data Available
What is Ultragenyx Pharmaceutical, Inc.’s market cap?
Ultragenyx Pharmaceutical, Inc.’s market cap is CHF2.76B.
When is Ultragenyx Pharmaceutical, Inc.’s upcoming earnings report date?
Ultragenyx Pharmaceutical, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 20 days.
How were Ultragenyx Pharmaceutical, Inc.’s earnings last quarter?
Ultragenyx Pharmaceutical, Inc. released its earnings results on May 05, 2026. The company reported -$1.48 earnings per share for the quarter, missing the consensus estimate of -$1.197 by -$0.283.
Is Ultragenyx Pharmaceutical, Inc. overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical, Inc.’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical, Inc. pay dividends?
Ultragenyx Pharmaceutical, Inc. does not currently pay dividends.
What is Ultragenyx Pharmaceutical, Inc.’s EPS estimate?
Ultragenyx Pharmaceutical, Inc.’s EPS estimate is -0.98.
How many shares outstanding does Ultragenyx Pharmaceutical, Inc. have?
Currently, no data Available
What happened to Ultragenyx Pharmaceutical, Inc.’s price movement after its last earnings report?
Ultragenyx Pharmaceutical, Inc. reported an EPS of -$1.48 in its last earnings report, missing expectations of -$1.197. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical, Inc.?
Currently, no hedge funds are holding shares in CH:UP0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ultragenyx Pharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF43.80 (― Downside)
CHF43.80 (― Downside)
Insider Transactions
Sold Shares
Worth CHF502.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.04%
12-Months-Change
Fundamentals
Return on Equity
1566.94%
Trailing 12-Months
Asset Growth
-1.21%
Trailing 12-Months
Company Description
Ultragenyx Pharmaceutical, Inc.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
UP0 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balances strong commercial execution, clear revenue guidance (reaffirmed $730M–$760M for 2026), rapid pipeline progress (two near-term PDUFAs and promising long-term GTX-102 data with Bayley-4 and MDRI signals), and manufacturing/launch readiness against meaningful near-term financial pressure (Q1 net loss of $185M, $197M cash used in operations, high operating expenses and restructuring charges). Management presented a credible path to profitability in 2027 with planned R&D/SG&A reductions and assumed PRV monetization, but timing uncertainty for Phase 3 readouts, quarter-to-quarter ordering variability and execution risks around launches and PRV realization remain. Overall the positives around product performance, global commercialization scale, and upcoming catalysts outweigh the near-term financial and execution risks.View all CH:UP0 earnings summariesUP0 Stock 12 Month Forecast
Average Price Target
$43.80
Travere Therapeutics
―
Xenon
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Mineralys Therapeutics, Inc.
―
Options Prices
Currently, No data available
---